Equine Herpesvirus 1 Myeloencephalopathy in Horses: Risks and Management

Equine herpesvirus 1 myeloencephalopathy is a neurological disease that can cause severe symptoms in horses, including loss of coordination, difficulty swallowing, and paralysis.

The virus is highly contagious and can be spread through direct contact with an infected horse's nasal discharge, saliva, or urine.

Horses with weakened immune systems are more susceptible to the virus, making them a higher risk for contracting the disease.

Equine herpesvirus 1 myeloencephalopathy is often fatal, with a mortality rate of up to 90% in some cases.

Suggestion: Equine Herpesvirus Ehv 1

Equine Herpesvirus 1 is a highly damaging virus that can affect horses in various ways. It typically causes respiratory disease, but can also infect other cell types throughout the body.

EHV-1 can infect white blood cells in the horse's bloodstream, and from there, it transfers to endothelial cells, the cells that line blood vessels. This can lead to inflammation and inappropriate blood clotting in affected vessels.

The virus is particularly damaging to endothelial cells, which can cause a reduction in blood supply to the brain or spinal cord. This can result in death of nervous tissue and symptoms of EHM.

EHV-1 myeloencephalopathy, or EHM, is a condition that results from widespread vascular or blood vessel injury after damage to the lining of the blood vessels of the blood-brain barrier.

Equine herpesvirus 1 myeloencephalopathy, or EHM, is a serious condition that affects horses. EHM primarily affects horses over 3 years of age, with some studies suggesting horses over 20 years of age may have an even higher risk.

Horses that develop a high fever during their initial illness are more likely to develop EHM. This is a crucial factor to consider, especially if your horse has been exposed to other horses.

Introducing new horses to the herd or exposure to other horses is common before EHM outbreaks. This can increase the risk of EHM, so it's essential to take precautions when introducing new horses.

Ponies and small horse breeds appear less likely to develop EHM. However, this doesn't mean they're completely immune, and it's still essential to take precautions.

Mares and fillies are more likely to develop EHM compared to males. This is something to keep in mind, especially if you have a female horse in your care.

Here are some key risk factors to consider:

Horses with equine herpesvirus 1 myeloencephalopathy can quickly become uncoordinated and weak, and have trouble standing. They may also have difficulty urinating and defecating.

The incubation period of EHV-1 infection is highly variable, but the average is 4 to 7 days, with most cases being 3 to 8 days, and some taking up to 14 days.

Horses may exhibit a fever, peaking at day 1 or 2 and 6 or 7 of incubation. The fever is often the first sign of infection.

Neurological signs may include loss of balance, hind-limb weakness, difficulty urinating, decreased tail tone, depression, and being down and unable to rise. It's essential to have a veterinarian assess horses demonstrating these signs.

The primary symptoms of equine herpesvirus myeloencephalopathy are uncoordinated movement, weakness, paralysis of the tail and anus, urinary incontinence, inability to rise after laying down, circling, difficulty swallowing, and head tilt.

Here are the primary symptoms of EHM:

Typically, weakness and incoordination primarily affect the hind limbs, but can also affect the front limbs in severe cases.

EHV-1 is commonly diagnosed from nasal swabs or blood samples by polymerase chain reaction (PCR), which amplifies the virus's DNA so that it can be detected. This method is used to detect the virus in horses displaying symptoms of nervous system infection or injury.

A complete neurologic examination is performed by veterinarians on horses showing symptoms, evaluating mentation, gait, posture, and the function of their limbs and tail. This examination helps identify what portion of the horse's nervous system is most severely affected.

Several diseases affecting the brain, spinal cord, and nerves can cause similar symptoms and neurologic examination findings to equine herpesvirus-1 myeloencephalopathy. To help identify the cause, veterinarians may perform additional tests, such as bloodwork to identify inflammation, evaluation of cerebrospinal fluid, X-rays to identify traumatic injuries or Wobbler's syndrome, viral, bacterial, or parasitic testing for specific diseases, and evaluation of the horse's feed and environment to identify potential toxins.

Suggestion: Equine Protozoal Myeloencephalitis Symptoms

Diagnostics that specifically confirm a diagnosis of EHM include testing cerebrospinal fluid for viral DNA, nasal swabs or blood collection to identify viral DNA, and blood testing to identify antibodies against the virus. However, these tests may return inconclusive results, even in horses with EHM.

In some cases, veterinarians may choose to treat the horse for EHM regardless of the test results, under the assumption that the horse has the disease. This is because the detection of virus through PCR analysis does not provide a diagnosis in the absence of clinical signs and/or other corroborating information.

Diagnostic Tests for EHM

Treatment for equine herpesvirus 1 myeloencephalopathy is primarily supportive, as there is no specific treatment available for the condition. Horses that exhibit sudden and severe neurological signs should be isolated immediately to prevent the spread of infection.

Supportive care typically involves maintaining hydration with fluids, and administering anti-inflammatories to reduce inflammation. In some cases, antiviral medications may be prescribed, although their effectiveness is minimal. Regular washing of the hind limbs is also crucial to prevent urine scalding.

Horses that become recumbent require frequent rolling to prevent pressure sores from developing on their skin. This can be done every 2-4 hours, and some recumbent horses may benefit from slings to hold them in a standing position to encourage use of their limbs.

Here is a list of supportive care measures that may be involved:

Treatment for equine herpesvirus myeloencephalopathy (EHM) is primarily supportive, as there is no specific treatment available.

Horses with EHM require immediate isolation to prevent the spread of infection to other horses.

Supportive care may involve administering intravenous nutrition and fluids, as well as manual evacuation of the bladder and rectum.

Regular washing of the hind limbs is also crucial to prevent urine scalding.

Steroids can be used to reduce inflammation, and antiviral medications may be prescribed.

Horses that become recumbent (cannot rise from laying down) need to be rolled frequently, every 2-4 hours, to prevent pressure sores from developing on their skin.

Some recumbent horses may benefit from slings to hold them in a standing position and encourage use of their limbs.

Horses that stay standing after a bout of incoordination have a good prognosis and typically improve within a few days.

It can take up to a year for coordination to return completely, and some horses may have permanent deficits.

Horses that continue to show signs of incoordination have a poor prognosis for future performance and riding, due to the risk of human injury from falling or stumbling.

In some cases, the remaining deficits may be so severe that handling the horse is dangerous, leading owners to consider euthanasia for safety concerns.

Horses that become recumbent have a poor prognosis for recovery, particularly if they stay recumbent for more than 24 hours.

Recumbent horses have a much higher risk of complications including pressure sores, colic, dehydration, and urinary tract infections.

The neurologic EHM strain of equine herpesvirus has a high mortality rate of 30-50%, making recovery challenging.

Horses that are able to remain standing usually have a better prognosis than those that are recumbent.

Recovery time can vary from several days to more than a year, with some horses taking up to a year to regain full coordination.

For your interest: English Bulldog Weight at 1 Year

Prevention and control of equine herpesvirus 1 myeloencephalopathy relies on two major strategies: biosecurity for uninfected horses and quarantine of potentially infected horses.

Employing routine biosecurity measures is key to preventing the spread of EHV-1. Implementing hand hygiene and basic cleaning and disinfection practices is crucial to minimize viral spread.

Horses that have been shipped long distances or new horses to the facility should be segregated for 14 days prior to entering the general population. This allows for a safe transition and reduces the risk of infection.

Restricting movement for 21 days of both people and horses where EHV-1 has been diagnosed is also essential. This includes changing clothes, shoes/boots, and washing hands when moving between equine facilities.

The EHV vaccine is a crucial aspect of prevention and control. We routinely vaccinate your horse for Rhinopneumonitis, which protects against EHV-1 and EHV-4.

However, it's essential to note that this vaccine only protects against the respiratory and abortion forms of EHV, not the mutated neurological form.

Quarantining new animals for at least 2 weeks is a must to prevent the spread of EHV.

Readers also liked: Equine Herpesvirus 1 Vaccine

Prevention is key to minimizing the risk of EHV-1 infection in horses. Biosecurity is crucial in preventing the spread of the virus.

Routine biosecurity measures should be implemented at all times to prevent disease outbreaks. This includes hand hygiene and basic cleaning and disinfection practices.

Horses that have been shipped long distances or are new to a facility should be segregated for 14 days prior to entering the general population. This helps prevent the spread of the virus to other horses.

EHV-1 vaccines may reduce viral shedding but are not protective against developing the neurological form of the disease. This is an important consideration for horse owners.

Restricting movement for 21 days of both people and horses where EHV-1 has been diagnosed is essential in preventing further spread of the virus. This includes changing clothes, shoes/boots, and washing hands when moving between equine facilities.

Facility owners should inform all service providers that have attended the facility within the previous week of the presence of the virus. This includes veterinarians, farriers, feed suppliers, and transporters, who can then take appropriate precautions.

Equine herpesvirus 1 myeloencephalopathy is a serious condition affecting horses worldwide. It's a neurological disorder caused by the equine herpesvirus 1 (EHV-1) virus.

The virus can cause a range of symptoms, from mild respiratory issues to severe neurological problems, including myeloencephalopathy. This condition can lead to a range of problems, including stumbling, weakness, and even paralysis.

In the United States, the first reported case of EHV-1 myeloencephalopathy occurred in 1973. Since then, there have been numerous outbreaks, highlighting the need for ongoing vigilance and awareness.

EHV-1 myeloencephalopathy can be fatal, especially if left untreated or if treatment is delayed. In fact, mortality rates can be as high as 50% or more in severe cases.

The virus can spread quickly through horse populations, often through contact with contaminated nasal secretions or feces. This emphasizes the importance of strict biosecurity measures to prevent the spread of the virus.

Young horses, especially those under the age of 2, are more susceptible to EHV-1 myeloencephalopathy. This is likely due to their developing immune systems, making them more vulnerable to infection.

Take a look at this: Equine Hoof Problems